The article mentions that IDEAYA Biosciences has received positive analyst ratings in the last 3 months, with an average 12-month price target of $29.14. This indicates a bullish sentiment among analysts, which could lead to a short-term positive impact on the stock price. The 16.56% increase in the average price target over the past month further supports this positive outlook.